QRICH1 mediates an intracellular checkpoint for CD8 + T cell activation via the CARD11 signalosome
Science Immunology · 14.03.2025 · 10 (105)
DOI: 10.1126/sciimmunol.adn8715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 14.03.2025. Verfasst von Nicole M Carter und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, CARD Signaling Adaptor Proteins, Lymphocyte Activation, Guanylate Cyclase. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Antigen receptor signaling pathways that control lymphocyte activation depend on signaling hubs and negative regulatory proteins to fine-tune signaling outputs to ensure host defense and avoid pathogenic responses. Caspase recruitment domain–containing protein 11 (CARD11) is a critical signaling scaffold that translates T cell receptor (TCR) triggering into the activation of nuclear factor κB (NF-κB), c-Jun N-terminal kinase (JNK), mechanistic target of rapamycin (mTOR), and Akt. Here, we identify glutamine-rich protein 1 (QRICH1) as a regulator of CARD11 signaling that mediates an intracellular checkpoint for CD8 + T cell activation. QRICH1 associates with CARD11 after TCR engagement and negatively regulates CARD11 signaling to NF-κB. QRICH1 binding to CARD11 is controlled by an autoregulatory intramolecular interaction between QRICH1 domains of previously uncharacterized function. QRICH1 controls the antigen-induced activation, proliferation, and effector status of CD8 + T cells by regulating numerous genes critical for CD8 + T cell function. Our results define a component of antigen receptor signaling circuitry that fine-tunes effector output in response to antigen recognition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biological Chemistry and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Nicole M Carter, Wihib D Hankore, Yong-Kang Yang, Shelby M Hutcherson, Wyatt Fales, Anushka Ghosh, Piyusha Mongia, Robert D Leone, Joel L Pomerantz
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Carter, N. M., Hankore, W. D., Yang, Y. K., Yang, C., Hutcherson, S. M., Fales, W., Ghosh, A., Mongia, P., Mackinnon, S., Brennan, A., Leone, R. D., & Pomerantz, J. L. (2025). QRICH1 mediates an intracellular checkpoint for CD8 + T cell activation via the CARD11 signalosome. Science Immunology, 10(105). https://doi.org/10.1126/sciimmunol.adn8715
Vancouver
Carter NM, Hankore WD, Yang YK, Yang C, Hutcherson SM, Fales W, et al. QRICH1 mediates an intracellular checkpoint for CD8 + T cell activation via the CARD11 signalosome. Science Immunology. 2025;10(105). doi:10.1126/sciimmunol.adn8715
BibTeX
@article{Carter2025,
author = {Carter, Nicole M and Hankore, Wihib D and Yang, Yong-Kang and Yang, Chao and Hutcherson, Shelby M and Fales, Wyatt and Ghosh, Anushka and Mongia, Piyusha and Mackinnon, Sophie and Brennan, Anna and Leone, Robert D and Pomerantz, Joel L},
title = {QRICH1 mediates an intracellular checkpoint for CD8 + T cell activation via the CARD11 signalosome},
journal = {Science Immunology},
year = {2025},
volume = {10},
number = {105},
doi = {10.1126/sciimmunol.adn8715}
}
EUVIMED